|
1
|
Caramori G, Casolari P, Cavallesco GN,
Giuffre S, Adcock I and Papi A: Mechanisms involved in lung cancer
development in COPD. Int J Biochem Cell Biol. 43:1030–1044. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
El-Zein RA, Young RP, Hopkins RJ and Etzel
CJ: Genetic predisposition to chronic obstructive pulmonary disease
and/or lung cancer: important considerations when evaluating risk.
Cancer Prev Res. 5:522–527. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Young RP, Hopkins RJ, Christmas T, Black
PN, Metcalf P and Gamble GD: COPD prevalence is increased in lung
cancer independence of age, gender and smoking history. Eur Respir
J. 34:380–386. 2009. View Article : Google Scholar
|
|
4
|
Wilson DO, Weissfeld JL, Balkan A, et al:
Association of radiographic emphysema and airflow obstruction with
lung cancer. Am J Respir Crit Care Med. 178:738–744. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Young R and Hopkins R: Lung function
predicts lung cancer. Eur Respir J. 35:1421–1422. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mannino DM, Aguayo SM, Petty TL and Redd
SC: Low lung function and incident lung cancer in the United
States: data from the first National Health and Nutrition
Examination Survey follow-up. Arch Intern Med. 163:1475–1480. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tockman MS, Anthonisen NR, Wright EC and
Donithan MG: Airways obstruction and the risk for lung cancer. Ann
Inter Med. 106:512–518. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wasswa-Kintu S, Gan WQ, Man SF, Pare PD
and Sin DD: Relationship between reduced forced expiratory volume
in one second and the risk of lung cancer: a systematic review and
meta-analysis. Thorax. 60:570–575. 2005.PubMed/NCBI
|
|
9
|
Young RP, Hopkins RJ and Eaton TE: Forced
expiratory volume in one second: not just a lung function test but
a marker of premature death from all causes. Eur Respir J.
30:616–622. 2007.PubMed/NCBI
|
|
10
|
Burrows B, Knudson RJ, Cline MG, et al:
Qualitative relationships between cigarette smoking and ventilatory
function. Am Rev Respir Dis. 115:195–205. 1977.PubMed/NCBI
|
|
11
|
Itoh K, Chiba T, Takahashi S, et al: An
Nef2/small Maf heterodimer mediates the induction of phase II
detoxifying enzyme genes through antioxidant response elements.
Biochem Biophys Res Commun. 236:313–322. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rushmore TH and Kong AN: Pharmacogenomics,
regulation and signaling pathways of phase I and II detoxifying
enzymes. Curr Drug Metab. 3:481–490. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ngyyen T, Yang CS and Pickett CB: The
pathways and molecular mechanisms regulating Nrf2 activation in
response to chemical stress. Free Radic Biol Med. 37:433–441. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Malhorta D, Thimmulappa R, Navas-Acien A,
et al: Decline in NRF2-regulated antioxidants in chronic
obstructive pulmonary disease lungs due to loss of its positive
regulator, DJ-1. Am J Respir Crit Care Med. 178:592–604. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cho HY, Reddy SP and Kleeberger SR: Nrf2
defends the lung from oxidative stress. Antioxid Redox Signal.
8:76–87. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ishii Y, Ito K, Morishima Y, et al:
Transcription factor NRF2 plays a pivotal role in protection
against elastase-induced pulmonary inflammation and emphysema. J
Immunol. 175:6968–6975. 2005. View Article : Google Scholar
|
|
17
|
Suzuki M, Betsuyaku T, Ito K, et al:
Down-regulated NF-E2-related factor 2 in pulmonary macrophages of
aged smokers and patients with chronic obstructive pulmonary
disease. Am J Respir Cell Mol Biol. 39:673–682. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Marzec JM, Christie JD, Reddy SP, et al:
Functional polymorphisms in the transcription factor NRF2 in humans
increase the risk of acute lung injury. FASEB J. 21:2237–2246.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Arisawa T, Tahara T, Shibata T, et al:
Nrf2 gene promoter polymorphism and gastric carcinogenesis.
Hepatogastroenterology. 55:750–754. 2008.PubMed/NCBI
|
|
20
|
Siedlinski M, Postma DS, Boer JM, et al:
Level and course of FEV1 in relation to polymorphisms in NFE2L2 and
KEAP1 in the general population. Respir Res. 10:732009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Masuko H, Sakamoto T, Kaneko Y, et al: An
interaction between Nrf2 polymorphisms and smoking status affects
annual decline in FEV1: a longitudinal retrospective cohort study.
BMC Med Genet. 12:972011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Spitz MR, Wei Q, Dong Q, Amos CI and Wu X:
Genetic susceptibility to lung cancer: the role of DNA damage and
repair. Cancer Epidemiol Biomarkers Prev. 12:689–698.
2003.PubMed/NCBI
|
|
23
|
Seibold MA and Schwartz DA: The lung: the
natural boundary between nature and nurture. Annu Rev Physiol.
73:457–478. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Muller T and Hengstermann A: Nrf2: friend
and foe in preventing cigarette smoking-dependent lung disease.
Chem Res Toxicol. 25:1805–1824. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shibata T, Ohta T, Tong KI, et al: Cancer
related mutations in NRF2 impair its recognition by Keap1-Cul3 E3
ligase and promote malignancy. Proc Natl Acad Sci USA.
105:13568–13573. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gresner P, Gromadzinska J and Wasowicz W:
Polymorphism of selected enzymes involved in detoxification and
biotransformation in relation to lung cancer. Lung Cancer. 57:1–25.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rotunno M, Yu K, Lubin JH, et al: Phase I
metabolic genes and risk of lung cancer: multiple polymorphisms and
mRNA expression. PLoS One. 4:e56522009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sasaki H, Hikosaka Y, Okuda K, et al:
NFE2L2 gene mutation in male Japanese squamous cell carcinoma of
the lung. J Thorac Oncol. 5:786–789. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rangasamy T, Cho CY, Thimmulappa RK, et
al: Genetic ablation of NRF2 enhances susceptibility to cigarette
smoke-induced emphysema in mice. J Clin Invest. 114:1248–1259.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yamamoto T, Yoh K, Kobayashi A, et al:
Identification of polymorphisms in the promoter region of the human
NRF2 gene. Biochem Biophys Res Commun. 321:72–79. 2004. View Article : Google Scholar : PubMed/NCBI
|
